A number of reports, including our previous study in 44 patients with stage III to IV melanoma treated with pembrolizumab1, have shown that high levels of circulating sEV PD-L1 before the treatment were associated with poorer clinical outcomes of immunotherapy. Here, CD274 is linked to melanoma.